期刊
NEUROPSYCHOBIOLOGY
卷 74, 期 3, 页码 169-175出版社
KARGER
DOI: 10.1159/000457903
关键词
Serotonin 3A and 3B receptor genes (HTR3A, HTR3B); Schizophrenia; Antipsychotic-induced weight gain; Pharmacogenetics
资金
- Sunovion Novartis
- TEVA
- Bioline Rx
- BI
- Envivo
- Companion Dx
- Janssen Pharma
- Lundbeck
- Allon
- Biomarin
- Eli Lilly
- F. Hoffmann-La Roche/Genentech
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Psychogenics
- Sepracor (Sunovion)
- Targacept
- Canadian Institutes of Health Research [MOP 142192]
- National Institutes of Health
- Centre for Addiction and Mental Health Foundation
- Canadian Biomarker Integration Network in Depression
- Ontario Brain Institute
Background: Schizophrenia (SCZ) is a chronic severe neuropsychiatric disorder, where pharmacological treatment has been hindered by adverse effects, including antipsychotic-induced weight gain (AIWG) and related complications. Genetic studies have been exploring the appetite regulation and energy homeostasis pathways in AIWG with some promising leads. The serotonin system has been shown to participate in these pathways. Methods: In the current study, we examined single nucleotide polymorphisms across the serotonin receptor genes HTR3A and HTR3B. Prospective weight change was assessed for a total of 149 SCZ patients of European ancestry. Results: We did not find the tested HTR3A or HTR3B gene markers to be associated with AIWG in our sample. Conclusion: Our preliminary findings suggest that these receptors may not play a major role in predicting AIWG. (C) 2017 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据